[Federal Register Volume 83, Number 112 (Monday, June 11, 2018)]
[Notices]
[Pages 26992-26993]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-12445]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY: Under Secretary of Defense for Personnel and Readiness, 
Department of Defense.

ACTION: Notice of Federal Advisory Committee meeting.

-----------------------------------------------------------------------

SUMMARY: The Department of Defense (DoD) is publishing this notice to 
announce that the following Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel will take place.

DATES: Open to the Public Thursday, July 12, 2018, from 9:00 a.m. to 
12:00 p.m.

ADDRESSES: The address of the open meeting is the Naval Heritage Center 
Theater, 701 Pennsylvania Avenue NW, Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: Col Paul J. Hoerner, U.S. Air Force, 
703-681-2890 (Voice), None (Facsimile), [email protected] (Email). Mailing address is 7700 Arlington 
Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: http://www.health.mil/About-MHS/Other-MHS-Organizations/Beneficiary-Advisory-Panel. The most up-to-date changes to the meeting agenda can be found 
on the website.

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 
U.S.C., Appendix, as amended), the Government in the Sunshine Act of 
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director of the Defense Health Agency, by 
the Pharmacy and Therapeutics Committee, regarding the Uniform 
Formulary.
    Purpose of the Meeting: The Department of Defense is publishing 
this notice to announce a Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as 
the Panel) will take place.

Agenda

1. Sign-In
2. Welcome and Opening Remarks
3. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item)
    a. Gastrointestinal-2 Miscellaneous Agents--Opioid-Induced 
Constipation Subclass
    b. Growth Stimulating Agents
    c. Pancreatic Enzyme Replacement Therapy Agents
4. Newly Approved Drugs Review
5. Pertinent Utilization Management Issues 6. Panel Discussions and 
Vote

    Meeting Accessibility: Meeting Accessibility: Pursuant to 5 U.S.C. 
552b, as amended, and 41 Code of Federal Regulations (CFR) 102-3.140 
through

[[Page 26993]]

102-3.165, and the availability of space, this meeting is open to the 
public. Seating is limited and will be provided only to the first 220 
people signing-in. All persons must sign-in legibly.
    Written Statements: Written Statements: Pursuant to 41 CFR 102-
3.140, the public or interested organizations may submit written 
statements to the membership of the Panel about its mission and/or the 
agenda to be addressed in this public meeting. Written statements 
should be submitted to the Panel's Designated Federal Officer (DFO).The 
DFO's contact information can be obtained previously in this 
announcement. Written comments or statements must be received by the 
committee DFO at least five (5) business days prior to the meeting so 
that they may be made available to the Panel for its consideration 
prior to the meeting. The DFO will review all submitted written 
statements and provide copies to all the committee members.

    Dated: June 6, 2018.
Shelly E. Finke,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2018-12445 Filed 6-8-18; 8:45 am]
 BILLING CODE 5001-06-P